TABLE 3

Summary of Moderator Analyses for Sleep Efficiency

CharacteristickbQ RegressionQ Residual
Methodological/design characteristics
 Length of time on medication, d70.05***Q(1) = 17.00, P < .001Q(5) = 8.59, P = .13
 Mean total dosage/d (in milligrams)40.02**Q(1) = 7.91, P = .005Q(2) = 8.89, P = .01
 Frequency of dosage/d50.25Q(1) = 3.63, P = .06Q(3) = 7.33, P = .06
 Frequency of dosage/wk50.13Q(1) = 2.25, P = .13Q(3) = 5.59, P = .13
 No. of nights of sleep assessed70.04*Q(1) = 6.24, P = .01Q(5) = 8.63, P = .13
 Method of sleep efficiency assessment7−0.81**Q(1) = 6.85, P = .008Q(5) = 7.81, P = .16
 Stimulant medication class70.46Q(1) = 1.72, P = .19Q(5) = 11.44, P = .04
 Funding source70.45Q(1) = 1.72, P = .19Q(5) = 11.44, P = .04
Sample characteristics
 Gender6−0.02**Q(1) = 10.40, P = .001Q(4) = 6.08, P = .19
 Age70.006Q(1) = 0.079, P = .77Q(5) = 8.62, P = .13
  • b, unstandardized regression coefficient; k, number of studies; Q Regression, homogeneity test for regression (ie, regression sum of squares); Q Residual, sum-of-squares residual (represents sampling error and random variation). ***P < .001; **P < .01; *P < .05.